Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Who May Qualify: - BCVA 1.0 logMAR or better in each eye (equivalent to 20/200) - Diagnosis of mild to moderate OAG or OHT in at least one eye - IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost Who Should NOT Join This Trial: - History of active ocular disease other than mild to moderate OAG/OHT - Prior use of any topical PGA without a clinically meaningful response - Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study - Use of other topical ocular concomitant medications 30 days prior - History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye. - Central corneal thickness in either eye \<470 or \>630 μm - Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled. - Participation in any investigational study within 30 days prior to Screening - Females who are pregnant, nursing, or not using birth control. Always talk to your doctor about whether this trial is right for you.